|
- Genentech: Press Releases | Monday, Mar 3, 2025
Genentech will also be introducing a new 25 mg vial configuration in the coming months to support the approval of TNKase for AIS “Today’s approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients,” said Levi Garraway, M D , Ph D , Genentech’s chief medical officer and head
- FDA Approves TNKase for Acute Ischemic Stroke | Powers Health
Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit
- Issue 6 - March 15, 2025 - pbdrx. com
On February 28, 2025, the U S Food and Drug Administration (FDA) approved Genentech’s TNKase® (tenecteplase) for the treatment of acute ischemic stroke in adult patients
- Genentech’s TNKase® Brings Fast Relief for Acute Ischemic Stroke . . .
The new approval brings a 25 mg vial configuration to TNKase, which will soon be available to support the treatment of stroke patients The medication shows effectiveness in decreasing the incidence of death risk in patients diagnosed with STEMI
- FDA Approves Tenecteplase for Acute Ischemic Stroke
The thrombolytic treatment, branded as TNKase and approved for adults, is administered as a 5-second IV bolus, upping the speed and simplicity of the 60-minute infusion of the previously approved alteplase (Activase; Genentech)
- TNKase® (tenecteplase) | Dosing for Acute Ischemic Stroke
The maximum recommended dose is 25 mg (5 mL) 1 During and following TNKase administration for the treatment of AIS, frequently monitor and control blood pressure 1 In patients without recent use of oral anticoagulants or heparin, TNKase treatment can be initiated prior to the availability of coagulation study results
- FDA Approves TNKase for Acute Ischemic Stroke - Drugs. com
Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit
- FDA Approves TNKase To Treat Ischemic Strokes In Adults - MSN
The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months
|
|
|